Taiho and Cullinan's zipalertinib hits its Phase 3 goal in lung cancer, setting up a fight with J&J's Rybrevant.
Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in…
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3…
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug…
Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head…
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
